**TO:** Sarah Chen (CFO), Dr. Marcus Webb (CMO), James Liu (VP Operations)
**FROM:** FDE Engagement Lead
**DATE:** 2026-04-09
**RE:** Stakeholder Alignment — AI Claims Processing Transformation, Greenfield Health Systems

---

## SITUATION SUMMARY

Greenfield Health Systems is moving to deploy an AI claims processing agent against a backdrop of real operational pressure: claims are averaging 8 days in cycle time, SLA penalties are accruing, and the $400K project budget is predicated on a meaningful reduction in processing staff. That combination has surfaced a genuine conflict between the CFO's cost reduction mandate, the CMO's clinical oversight requirements, and the VP of Operations' need for throughput gains that are durable, not illusory. This memo names that conflict directly, restates each executive's position faithfully, and proposes a phased resolution that all three parties can sign.

---

## STAKEHOLDER POSITIONS

**Sarah Chen, CFO:** The financial case for this project requires a 40% reduction in claims review staff — 8 FTEs — within 6 months. Her position is that 70% of claims are low-complexity and can be handled by the AI agent without clinical review, allowing staff to shift from processing to exception handling. Without the headcount reduction, the project does not return its investment and cannot be presented to the board.

**Dr. Marcus Webb, CMO:** Clinical decisions carry legal, regulatory, and patient safety weight that cannot be delegated to an AI system. His position is that any claim with clinical content — diagnostic imaging, specialist authorization, medical necessity determinations — must be reviewed by a physician or advanced practice provider before it is finalized. He is willing to reduce administrative staff but will not certify a system that bypasses clinical review, and claim denials cannot be approved without physician sign-off.

**James Liu, VP Operations:** Claims are currently sitting in queue for 9+ days, above the contractual threshold that triggers payer penalties. His position is that the project must deliver real cycle time reduction — not shifted workload — and that all parties, including the clinical review team, must commit to throughput SLAs. A solution that creates a new bottleneck in physician review does not solve his problem.

---

## THE CORE TENSION

The conflict is **cost reduction versus clinical oversight**, with an operational throughput constraint running underneath both.

The CFO's model assumes AI approves 70% of claims without clinical review — that is where the headcount savings come from. The CMO's model requires physician sign-off on all clinically relevant claims — that is where the liability protection comes from. These two positions, taken at face value, cannot coexist: either claims bypass clinical review (and the CMO's requirement is violated) or they don't (and the CFO's savings evaporate).

The VP of Operations' observation sharpens the tension: if physician review is retained at current throughput rates — where physicians read entire claim files from scratch — cycle time does not improve regardless of what the AI does upstream. Speed requires pre-screening; pre-screening requires trusting the agent's clinical flagging; trusting the flagging requires validated accuracy. That validation chain is what this resolution is built on.

---

## PROPOSED RESOLUTION

**A dual-path processing model, gated by validated clinical flagging.**

The agent triages every incoming claim. Claims with no clinical content — routine billing, eligibility checks, coding validation, prior auth completeness — are routed to the **Fast Path**, where the agent adjudicates end-to-end. Claims with clinical content are routed to the **Clinical Path**, where the agent pre-screens and packages a summary, and a physician reviews only that summary — not the full file.

Based on Dr. Webb's estimate that approximately 35% of claims carry genuine clinical content, the working split is: 65% Fast Path (agent-adjudicated), 35% Clinical Path (physician-reviewed). This resolves the arithmetic: the CFO achieves headcount reduction on the administrative side; the CMO retains physician oversight on every clinical claim; the VP of Operations gets cycle time improvement on both paths.

**Phased implementation:**

*Pre-Phase 1 — Historical Split Analysis (Weeks 1–3):* Before any shadow mode or staffing commitments begin, a retrospective sample of 90–180 days of closed claims is pulled and classified against Dr. Webb's clinical criteria — the same criteria that will define Clinical Path routing. The purpose is to validate or correct the 65/35 split assumption before the financial model and headcount targets are presented to the board. Gate criterion: split analysis reviewed and signed by Dr. Webb; if the measured clinical content rate deviates from 35% by more than 10 percentage points, Sarah Chen revises the headcount model before Phase 1 begins. This analysis also serves as the labeled ground-truth dataset for calibrating Phase 1 flagging accuracy.

*Phase 1 — Pilot and Validation (Months 1–3):* The agent runs in shadow mode alongside the current process. It performs administrative checks and applies clinical flagging logic. No claims are adjudicated by the agent alone; all outcomes are compared against current processor decisions. The purpose is to validate flagging accuracy before any staffing changes occur. Gate criterion: clinical flagging false-negative rate below 2% (i.e., the agent must not misclassify clinically complex claims as administrative). No headcount reduction is initiated until this gate is passed.

*Phase 2 — Operational Transition (Months 4–6):* Fast Path goes live. The agent adjudicates administrative claims end-to-end, with a human exception queue for edge cases. Clinical Path goes live with physician review of pre-screened summaries, targeting the 20 claims/hour throughput Dr. Webb confirmed is achievable with pre-screening. Admin staff reduction begins: from 20 to 13 FTEs, reflecting the shift in volume to agent processing. Clinical review staff is unchanged. SLA compliance is monitored weekly; if cycle time on either path exceeds 7 days, a remediation review is triggered before further transitions occur.

*Phase 3 — Steady State (Month 7+):* If Phase 2 metrics hold, admin staff reduces further to 7 FTEs. The CFO presents validated headcount and cycle time data to the board. Clinical review staffing remains a CMO decision, not subject to this project's reduction targets.

---

## RISKS AND MITIGATIONS

**Risk: Clinical flagging misclassifies a complex claim as administrative.** A false negative routes a clinically significant claim to the Fast Path without physician review — the CMO's core concern. *Mitigation:* Phase 1 shadow mode exists specifically to measure this rate. The 2% false-negative gate is a hard stop; the project does not proceed to live adjudication until it is passed. Post-launch, a random audit sample of Fast Path approvals is reviewed by clinical staff monthly.

**Risk: The 65/35 split assumption is wrong.** If clinical content is higher than 35%, physician throughput may be insufficient to meet SLAs, and the CFO's headcount savings shrink. *Mitigation:* The Pre-Phase 1 historical analysis measures the actual split against closed claims before any staffing commitments are made. If the historical rate deviates materially, the financial model is corrected before Phase 1 begins — not after Phase 2 has launched on wrong assumptions. Phase 1 shadow mode then confirms whether the AI's routing matches the historical ground truth.

**Risk: Physician review becomes a bottleneck even with pre-screening.** If the clinical summary package quality is poor, physicians revert to reading full files, and cycle time gains disappear. *Mitigation:* Physician throughput (claims reviewed per hour) is a Phase 2 SLA metric. If it falls below 15 claims/hour consistently, the summary template is revised before Phase 3 proceeds.

---

## SUCCESS CRITERIA

- Phase 1 gate: Clinical flagging false-negative rate < 2% over a 60-day shadow run
- Phase 2 SLA: Average cycle time below 7 days on both paths within 30 days of go-live
- Phase 2 throughput: Physician clinical review rate ≥ 15 claims/hour on pre-screened summaries
- Phase 3 economics: Net admin headcount reduction of 13 FTEs (from 20 to 7) confirmed by Month 6
- Ongoing: Denial appeal overturn rate does not increase from current baseline, indicating first-pass accuracy is maintained or improved

---

## NEXT STEPS

| Action | Owner | Due |
|---|---|---|
| Define and document clinical flagging criteria for Phase 1 | FDE Team + Dr. Webb | 2026-04-22 |
| Conduct historical claims split analysis (90–180 day sample) against Dr. Webb's clinical criteria | FDE Team + Dr. Webb | 2026-04-30 |
| Review historical split results and sign off on revised financial model if split deviates >10 pts | Sarah Chen + Dr. Webb | 2026-05-07 |
| Produce agent technical specification for claim triage and routing (Fast Path vs. Clinical Path) | FDE Team + Dr. Webb | 2026-04-22 |
| Produce agent technical specification for administrative checks | FDE Team | 2026-04-22 |
| Produce agent technical specification for clinical pre-screening and summary packaging | FDE Team + Dr. Webb | 2026-04-22 |
| Define Phase 1 measurement plan and audit protocol | FDE Team + James Liu | 2026-04-22 |
| Notify payers of expected SLA improvement timeline | James Liu | 2026-04-15 |
| Prepare conditional HR transition plan (activated only on Phase 1 gate pass) | Sarah Chen + HR | 2026-05-01 |

---

## AGREEMENT & SIGN-OFF

I have reviewed this memo and agree to the proposed approach:

&nbsp;

_____________________________ Date: ______
Sarah Chen, CFO

&nbsp;

_____________________________ Date: ______
Dr. Marcus Webb, Chief Medical Officer

&nbsp;

_____________________________ Date: ______
James Liu, VP Operations

&nbsp;

_____________________________ Date: ______
FDE Engagement Lead
